Tobira raises $31M in Series B

New Jersey biopharmaceutical company Tobira Therapeutics has raised $31 million in Series B financing, the company announced. A new investor, Novo A/S, led the round, with return investors Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners and Canaan Partners. The funding will be used to develop and bring to the market the company's antiviral compounds for the treatment of HIV.

North AmericaUSBriefs